Audited Financial Results
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Transgene Biotek reported a standalone net loss of Rs 165.29 lakhs for FY26 versus a loss of Rs 67.61 lakhs in FY25, continuing deterioration. Revenue from operations declined to Rs 21.12 lakhs from Rs 26.07 lakhs (approx 19% YoY). Other income dropped sharply to Rs 14.99 lakhs from Rs 78.35 lakhs. Finance costs surged over 4x to Rs 106.02 lakhs from Rs 24.30 lakhs, significantly impacting profitability. The company has negative shareholders' equity of Rs -919.98 lakhs on standalone basis, indicating balance sheet insolvency. Cash position is critically low at Rs 6.07 lakhs against total borrowings of Rs 1713.68 lakhs. Auditors M/s Vasavi & Co issued an unmodified opinion. The company is also facing multiple legal matters including appeals with SEBI (SAT), Enforcement Directorate, and NCLT. The HK subsidiary remains non-operational with unaudited books carried forward since 2015-16.
The company is in severe financial distress with negative net worth and mounting losses. The surge in finance costs and declining revenue signal heightened credit risk. Negative equity and pending legal cases suggest potential delisting risk or restructuring. Shareholders face high risk of value destruction.